Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a collaboration with MODAG GmbH to exclusively license and develop the small molecule candidate Anle138b, targeting neurological disorders like multiple system atrophy (MSA) and Parkinson’s disease (PD). The agreement allows Teva to develop and commercialize Anle138b and related compound Sery433, following favorable Phase 1 study results. The collaboration aims to address unmet medical needs in neurodegenerative diseases, potentially impacting thousands of patients annually.

Teva Pharmaceuticals presented new analyses from the COBRA study at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study, which included data from 99 mothers with multiple sclerosis treated with COPAXONE® (glatiramer acetate) during pregnancy and breastfeeding, found no safety concerns for infants. Specifically, there were no adverse effects on hospitalizations, antibiotic treatments, developmental delays, or growth during the first 18 months. This research addresses significant medical needs concerning treatment safety for women with MS.

U.S. federal judge dismisses AbbVie's trade secret lawsuit against Alvotech, affirming its path to market a biosimilar to Humira. This ruling, delivered on October 6, 2021, supports Alvotech's goal to provide affordable medications. Alvotech has submitted a Biologics License Application for its candidate, AVT02, which aims for FDA interchangeability designation with Humira. Teva Pharmaceuticals is Alvotech's exclusive U.S. commercialization partner for AVT02, enhancing market opportunities in a space valued at US$20 billion globally.

Teva Pharmaceuticals has released research indicating a growing demand among patients for awareness of drug manufacturing origins in Europe. The study reveals that 71% of patients want to know where their medicines are produced, citing concerns over the concentration of manufacturing overseas. 84% of those surveyed support government investments in local pharmaceutical production. The pandemic has highlighted vulnerabilities in global supply chains, necessitating a rebalancing in the pharmaceutical value chain. Teva asserts its commitment to invest close to 1 billion euros in European manufacturing facilities.

Teva Pharmaceutical Industries Ltd. will announce its third-quarter financial results on October 27, 2021, at 7:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, available via phone or a live webcast on Teva's website. Interested parties can join by dialing specific numbers based on their location. Teva is a leader in generic and specialty medicines, with over 3,500 products serving approximately 200 million patients daily.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced the presentation of 8 studies on AJOVY (fremanezumab) at the 25th World Congress of Neurology (WCN), occurring virtually from October 3-7, 2021. Highlights include pooled analyses on efficacy, safety, and quality of life improvements among diverse patient groups. The company will host an online symposium on October 3, focusing on healthcare disparities in migraine treatment. The studies aim to enhance understanding of migraine and promote inclusivity in clinical research.

Teva Pharmaceuticals has launched a national campaign called Inhaler Tales aimed at addressing improper inhaler use among asthma and COPD patients. An animated inhaler, voiced by actress Sarah Michelle Gellar, is central to the campaign, which raises awareness about the impact of inhaler misuse on disease control. A survey reveals that 40% of patients feel their respiratory conditions disrupt their lives, yet many are confident they use their inhalers correctly. However, only 45% adhere to their maintenance inhaler usage as prescribed, indicating a significant gap in effective disease management.

Teva Pharmaceuticals has reached a settlement with the Attorney General of Louisiana concerning opioid-related claims. The agreement, contingent upon state confirmation by November 2, 2021, includes a payment of $15 million over 18 years and the donation of $3 million worth of lifesaving medicines. Teva is also pursuing a national settlement and continues defending itself in ongoing litigation in states like New York and California. The company views this settlement as a significant step toward aiding those affected by opioid addiction.

Alvotech announced the FDA has deferred action on the application for AVT02, a proposed biosimilar to Humira, pending necessary facility assessments. The FDA can defer without identifying deficiencies when inspections cannot be completed due to factors such as travel restrictions. Alvotech collaborates with the FDA for safe coordination of inspections. They are the only company that has conducted a switching study supporting interchangeability for Humira's high-concentration biosimilar. Teva Pharmaceuticals is the exclusive partner for AVT02's commercialization in the U.S.